ライフサイエンスコーパス: PHA-L

1 PHA-L labeling showed that labeled corticothalamic termi

2 PHA-L was also placed into the dorsal raphe nuclei or nu

3 PHA-L was first injected into either the lateral or vent

4 PHA-L-immunoreactive (IR) fibers showing preterminal and

5 PHA-L-labeled fibers were observed in the ipsilateral po

6 PHA-L-labeled trigemino- and spinothalamic (TSTT) termin

7 etention of high levels of p27(Kip1) in IL-2/PHA-L-treated T cells bound to CDK2.

8 unostained with an antibody directed against PHA-L.

9 marker Phaseolus vulgaris leuco-agglutinin (PHA-L) was injected into individual PAG columns or adjoi

10 marker Phaseolus vulgaris leuco-agglutinin (PHA-L) with a particular focus on determining whether th

11 Approximately 19% of the BDA and PHA-L axon terminals examined originating from the commi

12 ers were injected into the dentate gyrus and PHA-L and BDA were injected into the entorhinal cortex t

13 the anterograde tracers BDA, neurobiotin and PHA-L in the host.

14 In PVH, NPY and PHA-L double-labeled fibers were found mainly in the par

15 al procedure for co-visualization of PRV and PHA-L was used to identify the sympathetic premotor regi

16 d based on random overlap of TrkB puncta and PHA-L--labeled afferents, 3 of 5 anti-TrkB antibodies te

17 ainst VGluT2, tyrosine hydroxylase (TH), and PHA-L.

18 ns of ChAT-immunoreactive neurons apposed by PHA-L-labeled input from medial VTA (mainly in vertical

19 s form synapses identical to those formed by PHA-L-immunolabeled axons with parvalbumin neurons; and

20 esizing neurons appeared to be innervated by PHA-L-containing axons.

21 he AGm, a double-labeling strategy combining PHA-L injections in the SNR and pressure injections of t

22 lyclonal antibodies were used to demonstrate PHA-L, tyrosine hydroxylase, dopamine beta-hydroxylase,

23 examined under a light microscope to detect PHA-L-labeled fibers.

24 ntire DMN or the mid-dorsal part of the DMN, PHA-L-containing axon varicosities were juxtaposed to ap

25 ng of the signal sequence resulted in PHA-E, PHA-L and GNA with heterogenous N-termini, with the majo

26 the tracer, simultaneous immunolabeling for PHA-L and proTRH peptides was performed and mapped in di

27 ined with Cuprolinic blue, and processed for PHA-L using the avidin biotin complex with diaminobenzid

28 roscopy determined the presence of VGluT2 in PHA-L- or WGA-positive terminals.

29 labeled tissue, we found that double-labeled PHA-L (+)/VGluT2 (+) axon terminals formed synaptic cont

30 by interleukin-2 (IL-2) and leucoagglutinin (PHA-L), whereas the expression of cyclin D2, CDK6, and C

31 ted with Phaseolus vulgaris leucoagglutinin (PHA-L) and labeled dextrans.

32 l tracer Phaseolus vulgaris leucoagglutinin (PHA-L) and performed double-label immunofluorescence wit

33 e tracer Phaseolus vulgaris leucoagglutinin (PHA-L) and the retrograde tracer FluoroGold in specific

34 beled by Phaseolus vulgaris leucoagglutinin (PHA-L) injected into the same MPO stimulation site.

35 beled by Phaseolus vulgaris leucoagglutinin (PHA-L) injections, whereas tyrosine hydroxylase (TH) was

36 ction of Phaseolus vulgaris leucoagglutinin (PHA-L) or an adeno-associated virus encoding wheat germ

37 e tracer Phaseolus vulgaris leucoagglutinin (PHA-L) or the retrograde tracer Texas Red-conjugated dex

38 e tracer Phaseolus vulgaris leucoagglutinin (PHA-L) was injected into one inferior colliculus of 10 a

39 t lectin Phaseolus vulgaris leucoagglutinin (PHA-L) was used to determine whether both of the lateral

40 tracer, Phaseolus vulgaris leucoagglutinin (PHA-L), was iontophresed into the ARH of female rats and

41 as using Phaseolus vulgaris leucoagglutinin (PHA-L).

42 tracers Phaseolus vulgaris-leucoagglutinin (PHA-L) and biotinylated dextran (BD) were injected into

43 rograde [Phasoleus vulgaris-leucoagglutinin (PHA-L) and biotinylated dextran amines (BDA)] tracers we

44 tracers Phaseolus vulgaris-leucoagglutinin (PHA-L) and biotinylated dextranamine (BD), direct spinal

45 (BDA) or Phaseolus vulgaris-leucoagglutinin (PHA-L) from the NTS with gold-silver labeling for tyrosi

46 tions of Phaseolus vulgaris-leucoagglutinin (PHA-L) in the SN, the labeled nigrotegmental fibers were

47 ning for Phaseolus vulgaris-leucoagglutinin (PHA-L) injected into the median raphe (MR) and parvalbum

48 e tracer Phaseolus vulgaris-leucoagglutinin (PHA-L) into discrete parts of the ventral tegmental area

49 e tracer Phaseolus vulgaris-leucoagglutinin (PHA-L) into lamina A of the lateral geniculate nucleus (

50 l tracer Phaseolus vulgaris-leucoagglutinin (PHA-L) into restricted regions of the PAG.

51 e tracer Phaseolus vulgaris-leucoagglutinin (PHA-L) into the pars reticulata of the substantia nigra

52 acing of Phaseolus vulgaris-leucoagglutinin (PHA-L) it was determined if parvalbumin-immunoreactive n

53 Phaseolus vulgaris-leucoagglutinin (PHA-L) was injected in discrete regions of the PAG, and

54 First, Phaseolus vulgaris-leucoagglutinin (PHA-L) was injected in the ventrolateral PAG in Sprague-

55 e tracer Phaseolus vulgaris-leucoagglutinin (PHA-L) were made in the BLA and detailed light microscop

56 BDA) and Phaseolus vulgaris-leucoagglutinin (PHA-L), into four subdivisions of OFC.

57 bstance, Phaseolus vulgaris-leucoagglutinin (PHA-L).

58 e tracer Phaseolus vulgaris-leucoagglutinin (PHA-L).

59 sport of Phaseolus vulgaris-leucoagglutinin (PHA-L); and gamma-aminobutyric acid (GABA)ergic terminal

60 tracers Phaseolus vulgaris-leucoagglutinin (PHA-L; for outputs) and cholera toxin B subunit (CTB; fo

61 nsport of Phaseolus vulgaris leucoagglutinin(PHA-L) or carbocyanine dyes, we characterize the POm tha

62 e tracer Phaseolus vulgaris leukoagglutinin (PHA-L).

63 tracers Phaseolus vulgaris-leuocoagglutinin (PHA-L) and biotinylated dextran amine (BDA).

64 At the ultrastructural level, PHA-L-labeled terminals were found to establish synaptic

65 pallidum co-localized only with TRD and not PHA-L, whereas pallidal MOR1 immunostaining co-localized

66 In the median eminence, NPY/PHA-L double-labeled fibers were found both in the inner

67 Confocal analysis demonstrated that NPY/PHA-L double-labeled fibers came in close apposition to

68 Approximately 95% of PHA-L-labeled terminals from the central lateral, midlin

69 rocessed for immunocytochemical detection of PHA-L and parvalbumin (PV) at light and electron microsc

70 cal observations made of the distribution of PHA-L labelled fibres and boutons in the mPFC.

71 Brainstem injections of PHA-L retrogradely labeled a few myenteric neurons in th

72 Stereotaxic injections of PHA-L were targeted to the mid-dorsal and mid-ventral po

73 ctivity was detected in the vast majority of PHA-L- or WGA-positive terminals forming asymmetric syna

74 were observed to be enmeshed in a network of PHA-L-containing fibers.

75 By electron microscopy, BDA- or PHA-L-labeled axon terminals originating from the NTS co

76 Highly restricted PHA-L injections were made in all four PAG columns throu

77 astructural level, about 40% of the selected PHA-L-labeled presynaptic terminals in the ventral palli

78 We found that PHA-L- or WGA-positive terminals from tagged VTA cells m

79 Finally, the PHA-L that spread to the nucleus of the solitary tract o

80 roscopic analysis confirmed that some of the PHA-L-labeled terminals established synaptic contacts wi

81 s were often found in close proximity to the PHA-L-labeled terminals.

82 ouble-labeled preparations using antisera to PHA-L and preproTRH 178-199, the latter as a marker for

83 tes within SM bundles were immunoreactive to PHA-L, tyrosine hydroxylase, and dopamine beta-hydroxyla

84 Injections of the tracers PHA-L or BDA into these auditory-responsive posterior th

85 rent fluorophores was performed to visualize PHA-L, NPY and CRH, with the aid of confocal microscopy.

86 globus pallidus, and internal capsule, where PHA-L-labeled terminals abutted cholinergic (choline ace

87 double tracer neuroanatomical study in which PHA-L was first iontophoretically ejected into either th

88 Controls included animals injected with PHA-L after intracranial deafferentations.

89 llidal MOR1 immunostaining co-localized with PHA-L and not TRD.